Fairfield Bush & CO. increased its holdings in shares of Seattle Genetics, Inc. (NASDAQ:SGEN) by 0.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,338 shares of the biotechnology company’s stock after acquiring an additional 100 shares during the period. Fairfield Bush & CO.’s holdings in Seattle Genetics were worth $1,308,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Amundi Pioneer Asset Management Inc. increased its stake in shares of Seattle Genetics by 11.2% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 192,129 shares of the biotechnology company’s stock worth $14,072,000 after purchasing an additional 19,394 shares in the last quarter. Candriam Luxembourg S.C.A. increased its stake in shares of Seattle Genetics by 76.1% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 379,904 shares of the biotechnology company’s stock worth $43,408,000 after purchasing an additional 164,124 shares in the last quarter. Strs Ohio increased its stake in shares of Seattle Genetics by 30.8% in the fourth quarter. Strs Ohio now owns 5,608 shares of the biotechnology company’s stock worth $640,000 after purchasing an additional 1,322 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Seattle Genetics during the fourth quarter worth $1,492,000. Finally, GWM Advisors LLC bought a new position in shares of Seattle Genetics during the fourth quarter worth $469,000. 94.33% of the stock is currently owned by institutional investors and hedge funds.

Shares of Seattle Genetics stock traded down $5.77 during trading on Wednesday, hitting $155.05. The stock had a trading volume of 1,245,537 shares, compared to its average volume of 1,535,574. The firm’s fifty day simple moving average is $148.99 and its 200-day simple moving average is $122.25. The stock has a market cap of $27.84 billion, a PE ratio of -82.71 and a beta of 1.42. Seattle Genetics, Inc. has a 12 month low of $63.02 and a 12 month high of $168.10.

Seattle Genetics (NASDAQ:SGEN) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.17). The firm had revenue of $234.51 million during the quarter, compared to the consensus estimate of $207.59 million. Seattle Genetics had a negative return on equity of 16.51% and a negative net margin of 32.81%. Seattle Genetics’s revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.08) EPS. Analysts forecast that Seattle Genetics, Inc. will post -2.8 earnings per share for the current year.

SGEN has been the subject of a number of research reports. Guggenheim upgraded shares of Seattle Genetics from a “neutral” rating to a “buy” rating in a research report on Friday, May 1st. Morgan Stanley upped their target price on shares of Seattle Genetics from $111.00 to $149.00 and gave the stock an “equal weight” rating in a research report on Monday, May 4th. Royal Bank of Canada upped their target price on shares of Seattle Genetics from $148.00 to $149.00 and gave the stock an “outperform” rating in a research report on Friday, May 1st. Goldman Sachs Group upgraded shares of Seattle Genetics from a “buy” rating to a “conviction-buy” rating in a research report on Tuesday, May 26th. Finally, Stifel Nicolaus upped their target price on shares of Seattle Genetics from $120.00 to $127.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. One analyst has rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $142.47.

In related news, Director Bros. Advisors Lp Baker sold 500,000 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $158.50, for a total value of $79,250,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Charles R. Romp sold 6,942 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $166.00, for a total transaction of $1,152,372.00. The disclosure for this sale can be found here. Insiders sold a total of 691,733 shares of company stock valued at $107,475,576 in the last 90 days. Company insiders own 31.10% of the company’s stock.

Seattle Genetics Company Profile

Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas.

See Also: Dead Cat Bounce

Want to see what other hedge funds are holding SGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seattle Genetics, Inc. (NASDAQ:SGEN).

Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.